- Trials with a EudraCT protocol (115)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
115 result(s) found for: Air quality.
Displaying page 1 of 6.
EudraCT Number: 2020-001322-54 | Sponsor Protocol Number: CS/2018/6632 | Start Date*: 2020-06-15 | ||||||||||||||||||||||||||
Sponsor Name:University Hospitals Bristol and Weston NHS Foundation Trust | ||||||||||||||||||||||||||||
Full Title: Carbon Dioxide Insufflation and Brain Protection During Open Heart Surgery: A Randomised Controlled Trial | ||||||||||||||||||||||||||||
Medical condition: Brain injury during open heart valve surgery | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004779-64 | Sponsor Protocol Number: ALMED-15-C2-054 | Start Date*: 2016-12-20 | |||||||||||
Sponsor Name:Air Liquide Santé International | |||||||||||||
Full Title: Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) for the Treatment of Peripheral Neuropathic Pain: a Randomised, International, Multicentre, Placebo-Controlled, Phenotype-stratified Phase IIa ... | |||||||||||||
Medical condition: Treatment Peripheral Neuropathic Pain | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003595-36 | Sponsor Protocol Number: ERN_11-0670 | Start Date*: 2012-04-26 |
Sponsor Name:University of Birmingham | ||
Full Title: Can muscle dysfunction in COPD be altered by oxygenation in patients with intermittent hypoxia on exertion? | ||
Medical condition: Chronic obstructive pulmonary disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-006736-22 | Sponsor Protocol Number: NAF 03.4.05.033 | Start Date*: 2007-02-14 |
Sponsor Name:Netherlands Asthma Foundation (NAF) [...] | ||
Full Title: An early diagnosis of asthma in young children by using non-invasive biomarkers of oxidative stress/airway inflammation, and early lung function measurements | ||
Medical condition: children with recurrent respiratory symptoms) | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Not Authorised) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004888-37 | Sponsor Protocol Number: FFR111158 | Start Date*: 2016-08-03 |
Sponsor Name:GlaxoSmithKline Research and Development Ltd | ||
Full Title: A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spr... | ||
Medical condition: Irritant (non-allergic) rhinitis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2016-000441-32 | Sponsor Protocol Number: REDOX2016 | Start Date*: 2016-10-27 |
Sponsor Name:Blekinge county council | ||
Full Title: REgistry-based randomized controlled trial of treatment Duration and mortality in long-term OXygen therapy (REDOX) A Multicenter, Phase III, Registry-Based, Randomized Controlled Trial (R-RCT) | ||
Medical condition: Chronic respiratory failure requiring LTOT (long-term oxygen treatment) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-000875-14 | Sponsor Protocol Number: ALS-7-05-A-401 | Start Date*: 2006-07-06 |
Sponsor Name:AIR LIQUIDE SANTE INTERNATIONAL | ||
Full Title: Short-, and long-term effects of the intra-operative nitrous oxide administration on the remifentanil-induced post-operative hyperalgesia, morphine consumption and long-term quality of life | ||
Medical condition: | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000372-42 | Sponsor Protocol Number: FSJD-ALINO-2011 | Start Date*: 2012-07-23 | |||||||||||
Sponsor Name:Fundació per la Recerca i la Docència Sant Joan de Déu | |||||||||||||
Full Title: A Phase IV, open-label, prospective, randomised clinical trial to evaluate the usefulness of measuring nitric oxide in exhaled air in the therapeutic management of adult patients with mild asthma | |||||||||||||
Medical condition: Treatment in non-smoking adult patients with mild persistent atopic bronchial asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003238-35 | Sponsor Protocol Number: 4_141221 | Start Date*: 2021-09-15 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: Effects of supplemental oxygen on systemic and cerebral hemodynamics in experimental hypovolemia: A randomized, phase IV, crossover study to study the effect of supplemental oxygen vs. room air on ... | |||||||||||||
Medical condition: Hypovolemia is the condition under investigation. Hypovolemia is induced by the "lower body negative pressure" (LBNP)-model. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001818-38 | Sponsor Protocol Number: EFC16750 | Start Date*: 2021-03-02 | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Developpement | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with mode... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003714-40 | Sponsor Protocol Number: HCQinpediatricILD | Start Date*: 2015-01-20 | |||||||||||
Sponsor Name:Klinikum der Ludwig-Maximilian-Universität München | |||||||||||||
Full Title: Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group to evaluate the efficacy and... | |||||||||||||
Medical condition: interstitial lung disease | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001819-24 | Sponsor Protocol Number: EFC16819 | Start Date*: 2021-04-29 | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Developpement | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with mode... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) BG (Trial now transitioned) CZ (Trial now transitioned) DK (Completed) HU (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004355-20 | Sponsor Protocol Number: 2013OE005B | Start Date*: 2014-03-20 | |||||||||||
Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust | |||||||||||||
Full Title: Randomised, controlled crossover trial to evaluate the Effects of Ambulatory Oxygen on health status in patients with Fibrotic Lung Disease (FLD) | |||||||||||||
Medical condition: Fibrotic Lung Diseases (FLDs) are chronic and progressive conditions resulting in substantial morbidity and mortality. The cardinal symptom of all fibrotic Interstitial Lung Diseases (ILDs) is shor... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004899-21 | Sponsor Protocol Number: TR02-104 | Start Date*: 2005-12-22 |
Sponsor Name:Transave, Inc. | ||
Full Title: Safety and tolerability study of SLIT(TM) Amikacin 500 mg once daily for 14 days by inhalation in cystic fibrosis study subjects chronically infected with Pseudomonas aeruginosa. | ||
Medical condition: Cystic Fibrosis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004389-17 | Sponsor Protocol Number: TR02-103 | Start Date*: 2005-12-28 |
Sponsor Name:Transave, Inc | ||
Full Title: SAFETY AND TOLERABILITY STUDY OF SLIT AMIKACIN 500 MG ONCE DAILY FOR 14 DAYS BY INHALATION IN CYSTIC FIBROSIS STUDY SUBJECTS CHRONICALLY INFECTED WITH PSEUDOMONAS AERUGINOSA | ||
Medical condition: Cystic Fibrosis with mild to moderate obstructive lung disease and chronic infection with Pseudomonas aeruginosa | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002482-34 | Sponsor Protocol Number: GAM10-10 | Start Date*: 2020-05-21 |
Sponsor Name:Octapharma USA | ||
Full Title: Efficacy and safety of Octagam 10% therapy in COVID-19 patients with severe disease progression | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-001958-10 | Sponsor Protocol Number: MD2018 | Start Date*: 2018-10-25 |
Sponsor Name:Abteilung für Hals-, Nasen- und Ohrenkrankheiten MUW, AKH Wien | ||
Full Title: Dexamethasone 21-dihydrogenphosphat and Triamcinolone acetonide in the treatment of Menière´s disease: a randomized, multicentric efficacy trial | ||
Medical condition: In our study we try to evaluate the effect of intratympanic Triamcinolon acetonide and Dexamethason 21-dihydrohenphosphat on vertigo control calculation, Hydrops MRI, vHIT (video head impuls test),... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2015-004143-39 | Sponsor Protocol Number: SHIP002 | Start Date*: 2016-08-09 | ||||||||||||||||
Sponsor Name:Erasmus MC | ||||||||||||||||||
Full Title: A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with t... | ||||||||||||||||||
Medical condition: Cystic Fibrosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) BE (Completed) DK (Completed) FR (Completed) ES (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-004344-30 | Sponsor Protocol Number: Moli1901-010A | Start Date*: 2005-10-31 |
Sponsor Name:AOP Orphan Pharmaceuticals AG | ||
Full Title: An Evaluation of the Safety and Tolerability of Multiple Dose Regimens of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis and Stable Lung Disease | ||
Medical condition: Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10,000 children. In cystic fibrosis chloride transport across the respiratory epithelium... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001873-10 | Sponsor Protocol Number: P160929J | Start Date*: 2020-04-03 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | |||||||||||||
Full Title: ANTIBIOTIC THERAPY IN RESPIRATORY TRACT INFECTIONS: AIR. A controlled randomized, open label, multicenter, non-inferiority trial evaluating an individualized antibiotic duration treatment strategy ... | |||||||||||||
Medical condition: Community acquired pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
